Hoping to Boost Revenue Growth, Gilead Acquires MYR in a $1.4 B Deal
Gilead sciences expects to expand its hepatitis pipeline by acquiring MYR GmbH in an all-cash deal worth $1.4 B (1.15 B euros), payable upon closing of the transaction. MYR, German …
Read More